Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) – a prospective cohort study
Authors
Michael Ka Lam Wong
Bryan Ping Yen Yan
Timothy Ho Him Kam (ORCID: https://orcid.org/0000-0002-9043-187X)
Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) – a prospective cohort study
Michael Ka Lam Wong, Bryan Ping Yen Yan, Timothy Ho Him Kam, Kevin Ka Ho Kam et al.
Journal
BMC Pulmonary Medicine
Topics
Pulmonary Hypertension Research and Treatments
article
Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) – a prospective cohort study
Michael Ka Lam Wong, Bryan Ping Yen Yan, Timothy Ho Him Kam, Kevin Ka Ho Kam, Guangming Tan
article en
Abstract
No abstract available for this paper.
Publication Tag
BMC Pulmonary MedicineVol. 26(1)
Institutions
Chinese University of Hong Kong (HK), Grantham Hospital (CN), Prince of Wales Hospital (CN)